Minerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $1.46 EPS

Minerva Neurosciences (NASDAQ:NERV) issued its quarterly earnings data on Friday. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($1.46), Zacks reports.

Minerva Neurosciences Stock Performance

Shares of NERV opened at $2.42 on Friday. The stock has a fifty day moving average of $3.22 and a two-hundred day moving average of $4.83. The company has a market capitalization of $115.56 million, a PE ratio of -0.08 and a beta of 0.09. Minerva Neurosciences has a fifty-two week low of $1.96 and a fifty-two week high of $8.80.

Wall Street Analyst Weigh In

NERV has been the subject of several analyst reports. Zacks Research raised shares of Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Wall Street Zen lowered shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Jefferies Financial Group raised shares of Minerva Neurosciences from a “hold” rating to a “mixed” rating and raised their price target for the stock from $7.50 to $10.00 in a research note on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, September 21st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.33.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.

Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.